Q-omics provides the consensus-scored MTCO1P17 profile across patient tissues and cancer cell-line models. MTCO1P17 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MTCO1P17 is differentially expressed in 3, with the highest sampling consensus in KIRP. Additionally, MTCO1P17 RNA expression shows 6,091 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and KIRP as cancer lineages where MTCO1P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO1P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO1P17 survival associations across molecular data types. MTCO1P17 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO1P17 RNA expression–survival associations across cancer types. High MTCO1P17 expression shows unfavorable associations in STAD, UCS, THYM and PCPG, but favorable associations in COAD and ACC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for MTCO1P17 RNA expression.
This table summarizes MTCO1P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO1P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO1P17 shows lower tumor expression in KIRP and STAD and higher tumor expression in KICH. The KIRP box plot shows higher MTCO1P17 RNA expression in normal versus tumor tissue (log2 FC = −0.138, t-test p = .042).
This table shows molecular features associated with MTCO1P17 in patient tissues and cancer cell lines. In patient samples, MTCO1P17 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
